Live Breaking News & Updates on Institute of microbiology chinese academy science

Stay informed with the latest breaking news from Institute of microbiology chinese academy science on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Institute of microbiology chinese academy science and stay connected to the pulse of your community

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer

Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer
SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company’s commercialization planning and operations.
“We are delighted to have Wei join Junshi’s senior leadership team,” said Mr. Jun Xiong, Chairman of Junshi Biosciences. “Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences’ commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company to meet the unmet needs of patients in China and the world."

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Guangzhou , Guangdong , China , Taiwan , Shanghai , Hong-kong , Suzhou , Jiangsu , Beijing , Maryland , United-states , Macao

Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014

Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Guangzhou , Guangdong , China , Taiwan , Shanghai , Hong-kong , Suzhou , Jiangsu , Beijing , Maryland , United-states , Macao

Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 | Comunicados | Edición USA

Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.

Guangzhou , Guangdong , China , Taiwan , Shanghai , Hong-kong , Suzhou , Jiangsu , Beijing , Maryland , United-states , Macao

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | Comunicados | Edición USA

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.

Guangzhou , Guangdong , China , Taiwan , Shanghai , United-states , Singapore , Suzhou , Jiangsu , Beijing , Maryland , Canada

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

June 3, 2021, 5:00 p.m. Eastern Daylight Time
“We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO’s plenary session, which traditionally features high-impact studies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced stage and treatment options are limited.”
In addition to the JUPITER-02 late-breaking abstract, ASCO accepted for publication or presentation more than two dozen additional abstracts, primarily investigator-sponsored studies, that evaluate the utility of toripalimab in a variety of cancer types including lung cancer, melanoma, urothelial carcinoma, gastroesophageal cancer and hepatobiliary malignancies.

Guangzhou , Guangdong , China , Shanghai , United-states , Suzhou , Jiangsu , Beijing , Maryland , Canada , San-francisco , California

Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

- Toripalimab data will also be featured in ASCO's official press program -SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences"

China , United-states , Shanghai , Canada , Chinese , Patricia-keegan , Junshi-bioscience , Eli-lilly , Mcdavid-stilwell , Denise-powell , Junshi-biosciences , Coherus-biosciences

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Guangzhou , Guangdong , China , Shanghai , United-states , Suzhou , Jiangsu , Beijing , Maryland , San-francisco , California , Chinese

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study | Comunicados | Edición USA

22 abr 2021
Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) has reached its pre-specified primary endpoints of Progression Free Survival (PFS) and Overall Survival (OS) at the interim analysis of the randomized, double-blind, placebo-controlled, multi-center, phase III clinical study “JUPITER-06” (Clinicaltrials.gov identifier: NCT03829969). Junshi Biosciences will communicate with the regulatory authorities regarding the supplemental New Drug Application (sNDA) in the near future.

Guangzhou , Guangdong , China , Shanghai , United-states , Suzhou , Jiangsu , Beijing , Maryland , San-francisco , California , Chinese

Junshi Biosciences: Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study

(0)
SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) has reached its pre-specified primary endpoints of Progression Free Survival (PFS) and Overall Survival (OS) at the interim analysis of the randomized, double-blind, placebo-controlled, multi-center, phase III clinical study "JUPITER-06" (Clinicaltrials.gov identifier: NCT03829969). Junshi Biosciences will communicate with the regulatory authorities regarding the supplemental New Drug Application (sNDA) in the near future.

Guangzhou , Guangdong , China , Shanghai , United-states , Suzhou , Jiangsu , Beijing , Maryland , San-francisco , California , Chinese